Terms: = Lung cancer AND PSA AND Diagnosis
139 results:
1. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
2. Ductal prostate cancer staging: Role of PSMA PET/CT.
Pepe P; Pepe L; Curduman M; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2024 Feb; 96(1):12132. PubMed ID: 38363231
[TBL] [Abstract] [Full Text] [Related]
3. Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate.
Cui Y; Lin J; Sun D; Zhang H; Diao T; Fu Q
J Cancer Res Clin Oncol; 2024 Jan; 150(2):45. PubMed ID: 38281261
[TBL] [Abstract] [Full Text] [Related]
4. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract] [Full Text] [Related]
5. Latin America and the Caribbean Code Against cancer 1st Edition: Medical interventions including hormone replacement therapy and cancer screening.
Baena A; Paolino M; Villarreal-Garza C; Torres G; Delgado L; Ruiz R; Canelo-Aybar C; Song Y; Feliu A; Maza M; Jeronimo J; Espina C; Almonte M
Cancer Epidemiol; 2023 Oct; 86 Suppl 1():102446. PubMed ID: 37852728
[TBL] [Abstract] [Full Text] [Related]
6. Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate cancer Patients After Definitive Treatment With psa Level ≤0.2 ng/mL.
Lu Y; Wilson ZJ; Xu G; Xu Z; Pan T; Wei P
Clin Nucl Med; 2023 Dec; 48(12):1021-1027. PubMed ID: 37801580
[TBL] [Abstract] [Full Text] [Related]
7. Secondary Squamous Cell Carcinoma of Prostate: A Case Report.
Chen Q; Ye J; Li X; Chen R; Zeng S
Arch Esp Urol; 2023 Jun; 76(4):309-312. PubMed ID: 37455530
[TBL] [Abstract] [Full Text] [Related]
8. Screening practices of cancer survivors and individuals whose family or friends had a cancer diagnoses-a nationally representative cross-sectional survey in Japan (INFORM Study 2020).
Akiyama M; Ishida N; Takahashi H; Takahashi M; Otsuki A; Sato Y; Saito J; Yaguchi-Saito A; Fujimori M; Kaji Y; Shimazu T;
J Cancer Surviv; 2023 Jun; 17(3):663-676. PubMed ID: 37041402
[TBL] [Abstract] [Full Text] [Related]
9. Systematic review of methods used to improve the efficacy of magnetic resonance in early detection of clinically significant prostate cancer.
Díaz-Fernández F; Celma A; Salazar A; Moreno O; López C; Cuadras M; Regis L; Planas J; Morote J; Trilla E
Actas Urol Esp (Engl Ed); 2023 Apr; 47(3):127-139. PubMed ID: 36462603
[TBL] [Abstract] [Full Text] [Related]
10. Osteolytic or mixed bone metastasis is not uncommon in patients with high-risk prostate cancer.
Kurokawa R; Kato S; Koyama H; Ishida M; Kurokawa M; Kuroda R; Ushiku T; Kume H; Abe O
Eur J Radiol; 2022 Dec; 157():110595. PubMed ID: 36356462
[TBL] [Abstract] [Full Text] [Related]
11. [Primary lung salivary gland-type duct carcinoma: a clinicopathological analysis of two cases and review of literature].
Li SL; Wu CY; Hou LK; Xie HK; Wu W; Zhang W; Zhang LP
Zhonghua Bing Li Xue Za Zhi; 2022 Mar; 51(3):218-223. PubMed ID: 35249285
[No Abstract] [Full Text] [Related]
12. Somatic-Type Yolk Sac Tumor Arising as a Predominant Component of Bladder Urothelial Carcinoma.
Collins K; Alkashash AM; Hwang M; Kaimakliotis HZ; Cheng L; Idrees MT
Int J Surg Pathol; 2022 Apr; 30(2):207-213. PubMed ID: 34255554
[TBL] [Abstract] [Full Text] [Related]
13. Prostate cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing psa Screening.
Pierre-Victor D; Parnes HL; Andriole GL; Pinsky PF
Urology; 2021 Sep; 155():62-69. PubMed ID: 34186135
[TBL] [Abstract] [Full Text] [Related]
14. [A Case of de novo Neuroendocrine Prostate cancer].
Kise H; Shiraishi T
Hinyokika Kiyo; 2021 Mar; 67(3):113-118. PubMed ID: 33957032
[TBL] [Abstract] [Full Text] [Related]
15. Trends in population-based cancer survival in Slovenia.
Zadnik V; Zagar T; Lokar K; Tomsic S; Konjevic AD; Zakotnik B
Radiol Oncol; 2021 Jan; 55(1):42-49. PubMed ID: 33885247
[TBL] [Abstract] [Full Text] [Related]
16. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia.
Khan S; Wolin KY; Pakpahan R; Grubb RL; Colditz GA; Ragard L; Mabie J; Breyer BN; Andriole GL; Sutcliffe S
BMC Urol; 2021 Mar; 21(1):47. PubMed ID: 33773592
[TBL] [Abstract] [Full Text] [Related]
17. Overdiagnosis in urologic cancer : For World Journal of Urology Symposium on active surveillance in prostate and renal cancer.
Klotz L
World J Urol; 2022 Jan; 40(1):1-8. PubMed ID: 33492425
[TBL] [Abstract] [Full Text] [Related]
18. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable psa in Prostate cancer Patients After Definitive Treatment?
Teyateeti A; Teyateeti A; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 Sep; 45(9):672-678. PubMed ID: 32604105
[TBL] [Abstract] [Full Text] [Related]
19. Acinar with ductal and mucinous adenocarcinoma of prostate cancer complicated with lung metastasis: a case report and literature review.
Cui Y; Miao C; Xu A; Wang Z; Liu B
Ann Palliat Med; 2021 Feb; 10(2):2366-2370. PubMed ID: 32576002
[TBL] [Abstract] [Full Text] [Related]
20. Detection and Prognosis of Prostate cancer Using Blood-Based Biomarkers.
Jin W; Fei X; Wang X; Song Y; Chen F
Mediators Inflamm; 2020; 2020():8730608. PubMed ID: 32454797
[TBL] [Abstract] [Full Text] [Related]
[Next]
